Company: CRNX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001658247-25-000019
Chunk: 25

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
izedLossesFairMarketValueAvailable-for-sale investment securities:U.S. government obligations$542,962 $417 $(35)$543,344 Agency obligations57,986 2 (57)57,931 Corporate debt securities487,613 818 (182)488,249 Total$1,088,561 $1,237 $(274)$1,089,524 As of September 30, 2025 and December 31, 2024, available-for-sale investment securities by contractual maturity were as follows (in thousands):As of September 30, 2025As of December 31, 2024AmortizedCostFairMarketValueAmortizedCostFairMarketValueAvailable-for-sale investment securities:Due in one year or less$765,926 $767,377 $621,499 $622,161 Due after one year through five years213,221 214,013 467,062 467,363 Total$979,147 $981,390 $1,088,561 $1,089,524 The following is a summary of the available-for-sale investment securities by length of time in a net loss position as of September 30, 2025 and December 31, 2024 (in thousands):As of September 30, 2025Less Than 12 MonthsMore Than 12 MonthsTotalFairMarketValueGrossUnrealizedLossesFairMarketValueGrossUnrealizedLossesFairMarketValueGrossUnrealizedLossesAvailable-for-sale investment securities:U.S. government obligations$14,918 $(1)$— $— $14,918 $(1)Agency obligations29,954 (44)— — 29,954 (44)Corporate debt securities41,800 (22)— — 41,800 (22)Total$86,672 $(67)$— $— $86,672 $(67)

9

Table of Contents

As of December 31, 2024Less Than 12 MonthsMore Than 12 MonthsTotalFairMarketValueGrossUnrealizedLossesFairMarketValueGrossUnrealizedLossesFairMarketValueGrossUnrealizedLossesAvailable-for-sale investment securities:U.S. government obligations$19,953 $(35)$— $— $19,953 $(35)Agency obligations47,936 (57)—